Exelixis, Inc. engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cancer, metabolic, and cardiovascular disorders. The company's compounds primarily target multiple receptor tyrosine kinases simultaneously.
Exelixis, Inc. does not currently have any hardcopy reports on AnnualReports.co.uk. Click the button below to request a report when hardcopies become available.
Shipping Information
Please fill out the form below and click "Place Order" to complete your order.